SCHEDULE 13G/A: BlackRock Discloses 14.8% Stake in Avanos Medical, Inc. via Latest SEC Filing
Beneficial Ownership Report
BlackRock, Inc. has filed an Amendment No. 3 to Schedule 13G, reporting a beneficial ownership of 14.8% in Avanos Medical, Inc. as of March 31, 2025.
Summary
- BlackRock, Inc. has filed an Amendment No. 3 to Schedule 13G concerning its beneficial ownership in AVANOS MEDICAL, INC.
- As of the event date of March 31, 2025, BlackRock, Inc. beneficially owns an aggregate of 6,826,353 shares of Avanos Medical, Inc. Common Stock.
- This ownership represents 14.8% of the class of securities.
- BlackRock, Inc. holds sole voting power over 6,738,836 shares and sole dispositive power over 6,826,353 shares.
- No shared voting or dispositive power is reported.
- The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of the issuer.
- BlackRock Fund Advisors, a subsidiary of BlackRock, Inc., beneficially owns 5% or greater of the outstanding shares.
- iShares Core S&P Small-Cap ETF also holds an interest exceeding five percent of the total outstanding common stock.
Sentiment
Score: 5
Explanation: The document is a factual, compliance-driven filing reporting beneficial ownership, with no inherent positive or negative sentiment regarding the issuer's performance or outlook.
Industry Context
This filing is a routine disclosure by a major institutional asset manager, BlackRock, Inc., detailing its passive investment stake in Avanos Medical, Inc. Such filings provide transparency on significant ownership positions within publicly traded companies, which is standard practice in the financial industry.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, confirming a large, passive investment.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of Event Which Requires Filing of this Statement |
| 04/30/2025 | Signature Date of the Schedule 13G Amendment |
Keywords
BlackRock, Avanos Medical, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management, Healthcare, Medical Devices
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.